Evaluation of FT819 in the Treatment of B-cell Mediated Autoimmune Diseases

The primary objective of this study is to evaluate the clinical application of FT819 in patients diagnosed with B-cell mediated autoimmune diseases. This investigation aims to assess the therapeutic potential of the intervention in modulating disease progression. There are no secondary objectives specified.

The study includes a total of 194 patients. The participant population consists of both males and females within the age ranges corresponding to codes 3 and 4. All subjects are diagnosed with B-cell mediated autoimmune diseases.

This Phase 1 clinical trial investigates the efficacy and safety of FT819 in patients diagnosed with B-cell mediated autoimmune diseases. The research methodology involves a systematic evaluation of the investigational product. The study protocol includes a screening visit to determine eligibility, followed by scheduled follow-up visits to monitor clinical responses and safety parameters. The sequence concludes with an end-of-study visit. The total duration of the research period is estimated to extend from October 2025 to December 2042. Specific conditions necessitating early termination from the study are determined by predefined clinical safety criteria or protocol deviations.

Efficacy assessment in this clinical trial for B-cell mediated autoimmune diseases is not specified.